NHS-life sciences partnership

 
Drug development There will be a £180m catalyst fund to help commercialise new medical treatments

Related Stories

There has been widespread speculation about how David Cameron plans to accelerate drug development for NHS patients.

One newspaper headline talked of plans to share patient records with private health care companies, "including some that use animals in clinical tests". It spoke to an unnamed senior executive of a drugs company which it described as "well-known for animal testing".

The plain fact is that all companies developing new medicines do animal research.

Another report spoke of "controversial plans" which could mean giving pharmaceutical companies more "freedom to run clinical trials inside hospitals".

Controversial perhaps, but this has been happening for years. GlaxoSmithKline, one of the world's biggest pharmaceutical firms, has a clinical trials unit within Addenbrookes hospital in Cambridge and a clinical imaging centre at Hammersmith hospital in west London.

So let's turn to the speech itself. It is partly a government response to the difficult economic times facing the life sciences industry.

This is a vital sector employing more than 160,000 people in 4,500 companies with an annual turnover of £50 billion. But in many areas it is struggling.

The innovation drugs pipeline is not flowing like it used to and the number of medicines in late stage development has declined.

Coupled to that are the soaring costs of conducting clinical trials.

I wrote last week about the dramatic decline in clinical trials in the UK, from 6% of the global total in 2000, to 1.4% last year.

This is not just a British problem. Other European countries are facing a challenge from the emergence of countries like India as trial venues.

The most tangible blow to pharma R&D came earlier this year Pfizer announced it was closing its research facility in Kent, which employs 2,400 people, and where the drug Viagra was developed.

So it's in that climate that the Prime Minister has now announced that life sciences in Britain are at a crossroads:

"Pressure on healthcare budgets in the West, emerging economies in the East, an ageing population, an explosion of knowledge - all creating a new paradigm for life sciences. And in this new paradigm, we must ensure that the UK stays ahead."

Mr Cameron says the coalition's strategy is to open up the health service to new ideas and for the NHS to be working "hand-in-glove with industry".

That has left some very uncomfortable, especially to plan to give greater access to patient records to the pharmaceutical industry.

The NHS already has a mass of hospital data available to researchers, but this plan would go further, adding GP records throughout England, all of which would be anonymised.

Shadow health secretary Andy Burnham expressed concern that it would put confidentiality at risk: "The Prime Minister has to tread carefully. What he calls red tape others might see as essential safeguards. Some areas need proper regulation and patient records is certainly one of them."

The devil will be in the detail here. It will certainly be of benefit to researchers to have comprehensive access to NHS data, but it would have to be anonymised in such a way that would prevent any attempt to de-code the data to identify individuals.

Mr Cameron has also announced a £180 million catalyst fund to help commercialise new medical treatments.

I'm told a key aim here is to help small teams of scientists - often in universities - to mount a "proof of concept" trial. This might cost half a million pounds and take the therapy to the point where investors or the pharmaceutical industry gets involved.

Downing Street also wants to accelerate the licensing process of experimental treatments so that patients with serious conditions like brain and lung cancer could get earlier access to medicines.

Bear in mind though that fewer and fewer British patients are benefiting from new therapies on clinical trials because of the shift overseas. And while £180 million will be welcomed, that is less than the cost of bringing one new medicine to market from start to finish.

 
Fergus Walsh Article written by Fergus Walsh Fergus Walsh Medical correspondent

Ebola trial volunteer immunised

A trial of an experimental vaccine against the Ebola virus has begun in Oxford.

Read full article

More on This Story

Related Stories

Comments

This entry is now closed for comments

Jump to comments pagination
 
  • rate this
    0

    Comment number 10.

    Good idea - this will vastly speed-up & improve the UK's Mefical research.
    The Data will NOT identify the Patient, so let's get on with it.
    Ignore the EVER-present 'Doom-sayers' and welcome advance...

  • rate this
    0

    Comment number 9.

    Like the article says, a lot of this work is already underway. Once again we have the Tories claiming to be the ones who came up with these ideas when, in fact, they weren't. I support being a world leader on health but NOT privatization of the NHS.

    It's time for people to stand up to protect the NHS. We don't want to have 55 million people with no access to healthcare like the United States.

  • rate this
    +1

    Comment number 8.

    I wish I didn't have the contempt I have for the tories.I wish it was difficult to see through their front.It would be great to see veins of humanity on the carcasses of their proposals.Just the closer you get,the more obvious it is.Unmistakable.There.

  • rate this
    0

    Comment number 7.

    Phil has made an important point - many people are naive to the stringent informatics governance in place to minimise error. However, it only takes one NHS memory stick to go missing and public confidence is undermined; even if the stick has nothing on it. These are important issues needing to be discussed at a national level and not just on blogs.

  • rate this
    +1

    Comment number 6.

    I have advanced lung cancer. The treatment I am on was only licenced by NICE about a year ago despite the clinical trials starting in 1996! This proposal is great news for people like me who depend on research and new drugs being available. If you asked anyone in the same situation as me I don't think anyone would object if it were to save their lives or help them live a little longer.

 

Comments 5 of 10

 

Features

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.